UNSPSC 51332511: Melperone

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J8WA3K39B7. European Medicines Agency schedules Melperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08727MIG. Melperone generally arises in the molecular formula C16H22FNO.

The term MELPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) MELPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule melperone under HS 29333999 and SITC 51574. As of Q4 2014, MELPERONE remains the US FDA Preferred Term for this commodity. Melperone bears US NLM identifiers UMLS ID C0066477 and NCI Concept Code C73293. SMILES: FC1CCC(C(=O)CCCN2CCC(CC2)C)CC1.

UNSPSC 51332511 Melperone is a Commodity code that in recent state and local procurement activity spans emergency medical supplies, generic pharmaceuticals, and over-the-counter products distributed through government health systems, public health departments, and multistate cooperative purchasing consortia. The code's nominal scope (melperone, a psychiatric medication) does not align with the mix of solicitations actually posted under it—recent opportunities show state and local buyers acquiring naloxone kits, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering procurement for Minnesota, Oregon, and other participating jurisdictions). The work involves manufacturer relationships with established drug wholesalers, compliance with FDA regulations and the Drug Supply Chain Security Act, and submission of detailed product specifications including National Drug Codes and pricing structures.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendor relationships with AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. as authorized wholesalers, with awards effective July 1, 2026. Manufacturers must demonstrate cGMP certification, DSCSA compliance, and maintain commercial general liability insurance of at least $5 million per occurrence. The code shows limited recent alignment with its nominal pharmaceutical classification; pursuit depends on vendor capability to serve public health procurement channels through established wholesale distribution networks.